|
Upadacitinib |
2-Bromo-5H-pyrrolo[2,3-b]pyrazine |
875781-43-4 |
|
|
N-Tosyl-5-bromo-4,7-diazaindole |
1201186-54-0 |
|
|
|
Carbamic acid,N-[5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]-, ethyl este |
1869118-24-0 |
|
Upadacitinib (ABT-494) is a JAK1-selective inhibitor developed by AbbVie for the treatment of moderate to severe rheumatoid arthritis and other inflammatory conditions . The synthesis of Upadacitinib involves the construction of a complex imidazopyrrolopyrazine core through sequential cross-coupling and cyclization reactions, with the intermediates listed above serving as key building blocks in the synthetic route .
To obtain quotations, samples, or technical data for Upadacitinib intermediates, please contact the Cosperpharm sales and technical team. We will respond to your inquiry within 1 business day.
-
